ImageneBio vs SAB Biotherapeutics
IMA and SABS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMA and SABS compare
SAB Biotherapeutics is the larger company, worth 6.7 times as much as ImageneBio ($283M against $42.2M).
SAB Biotherapeutics scores higher on the StockData Score (8 against 7 for ImageneBio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMA | SABS |
|---|---|---|
| Size and price | ||
| Market cap | $42.2M | $283M |
| Share price | $3.72 | $3.11 |
| Change, 1 year | −54.6% | −2.8% |
| Change, 5 years | −98.0% | −97.2% |
| Beta (5Y) | 1.18 | 1.39 |
| Employees | 15 | 86 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.3× (better) | 1.3× |
| Growth | ||
| Revenue growth, 5Y average | −38.6% | – |
| Net income growth (TTM) | – | −530% |
| Profitability | ||
| Return on equity | −32.3% (better) | −42.8% |
| Return on invested capital | – | −83.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 16.17 (better) | 7.28 |
| Altman Z-score | −0.99 | 5.11 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 54.9% | 75.2% |
| Held by insiders | 52.9% | 30.2% |
| Insider net buying, 12 months | $78.5K | – |
| Short interest, % of float | 0.86% | 7.9% |
Go deeper
- IMA stock overview
- IMA income statement
- IMA valuation and score
- SABS stock overview
- SABS income statement
- SABS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.